全链造“肽”，质造全球

Full-Chain Peptide Manufacturing, Global Quality Excellence

海南中和药业亮相2026第二十四届中国CPHI展会，多肽API&制剂一体化实力出圈

Hainan Zhonghe Pharmaceutical Shines at CPHI China 2026, Demonstrating Integrated API & Formulation Capabilities

近日，2026第二十四届世界制药原料中国展（CPHI China）在上海新国际博览中心圆满落幕。作为亚太地区极具影响力的制药全产业链盛会，本次展会汇聚全球3900 余家医药企业、十余万海内外专业客商，聚焦原料药、制剂、生物创新药、合规研发等核心领域，搭建国际医药交流与合作的核心平台。

Recently, the 24th CPHI China concluded successfully at the Shanghai New International Expo Center (SNIEC). As a highly influential pharmaceutical industry event in the Asia-Pacific region, this exhibition gathered over 3,900 pharmaceutical enterprises and more than 100,000 domestic and international professional visitors, focusing on core areas such as APIs, formulations, biopharmaceutical innovation, and regulatory compliance R&D, establishing a central platform for international pharmaceutical exchange and cooperation.

海南中和药业股份有限公司作为集多肽原料药（API）研发生产、高端多肽制剂落地、一体化CMC解决方案于一体的综合型制药企业，携核心多肽API、成熟制剂产品及定制化生产服务重磅参展，凭借全产业链、高合规、高品质的多肽核心优势，收获海内外客商高度认可。区别于行业单一原料或单一制剂生产企业，我司深耕多肽医药领域30余年，构建了从多肽分子研发、API规模化生产、制剂工艺优化到商业化落地的完整闭环产业链，是国内少数具备多肽原料药与终端制剂同步研发、同步量产、同步合规申报能力的企业，彻底打通多肽药物上下游壁垒，为全球合作伙伴提供更稳定、更省心、更高性价比的全链条医药解决方案。

Hainan Zhonghe Pharmaceutical Co., Ltd., as a comprehensive pharmaceutical enterprise integrating peptide API R&D and manufacturing, high-end peptide formulation commercialization, and integrated CMC solutions, made a significant presence at the exhibition with core peptide APIs, mature formulation products, and customized manufacturing services. Leveraging its core advantages in full-chain integration, high compliance, and superior quality, the company received high recognition from domestic and international customers. Unlike industry peers focusing solely on raw materials or formulations, Hainan Zhonghe has been deeply engaged in the peptide pharmaceutical field for over 30 years, establishing a complete closed-loop industrial chain spanning from peptide molecular R&D, API scale-up production, formulation process optimization to commercialization. The company is one of the few domestic enterprises capable of simultaneous R&D, scale-up manufacturing, and regulatory compliance filing for both peptide APIs and finished formulations, effectively bridging the upstream and downstream barriers in peptide drug development. This enables the company to provide global partners with more stable, hassle-free, and cost-effective full-chain pharmaceutical solutions.

● 全管线矩阵，覆盖多肽主流治疗领域

Comprehensive Pipeline Matrix Spanning Mainstream Peptide Therapeutic Areas

本次展会，我司集中展出多款市场认可度高、临床应用广泛的核心多肽产品，管线覆盖免疫调节、肿瘤治疗、消化急救、泌尿妇科、肝病诊疗等主流临床赛道，同时布局特色核苷类药物，形成差异化产品竞争力。原料药端主打胸腺法新、醋酸去氨加压素、醋酸阿托西班、醋酸西曲瑞克、醋酸奥曲肽等刚需多肽API，可稳定供应标准多肽、修饰多肽等多品类原料；制剂端拥有冻干粉针、小容量注射剂、片剂、胶囊剂等多条成熟生产线，核心在售制剂涵盖注射用胸腺五肽、注射用胸腺法新、注射用醋酸西曲瑞克、醋酸阿托西班注射液、卡贝缩宫素注射液、醋酸加尼瑞克注射液等多款经典品种，实现原料自主可控、制剂临床落地、品类多元定制的完备格局，全面适配创新药研发、仿制药申报、临床用药供应、制剂委托生产等多元化市场需求。

At CPHI China 2026, our company showcased a concentrated portfolio of core peptide products with high market recognition and extensive clinical application. Our pipeline covers mainstream therapeutic areas including immune regulation, oncology treatment, digestive emergency, urology and gynecology, and liver disease diagnosis and treatment, while also strategically positioning specialty nucleoside drugs to form differentiated product competitiveness. On the API side, we focus on essential peptide APIs including Thymalfasin, Desmopressin Acetate, Atosiban Acetate, Cetrorelix Acetate, and Octreotide Acetate, with stable supply capabilities for standard peptides, modified peptides, and other categories. On the formulation side, we possess multiple mature production lines for lyophilized powder for injection, small-volume injections, tablets, and capsules. Our core marketed formulations encompass Thymopentin for Injection, Thymalfasin for Injection, Cetrorelix Acetate for Injection, Atosiban Acetate Injection, Carbetocin Injection, and Ganirelix Acetate Injection, among other classic drug products—achieving a comprehensive structure featuring autonomous API control, clinical formulation commercialization, and diversified customization, fully adaptable to diversified market demands including innovative drug R&D, generic drug marketing authorization submission, clinical supply, and contract manufacturing of drug products.

同时，公司展出核心在研创新产品——司美格鲁肽原料药及注射液，深度布局当下高景气代谢慢病赛道，成为本次展会核心亮点品种，吸引多家客商驻足交流。中和药业依托数十年多肽合成技术积淀与API+制剂一体化平台，实现司美格鲁肽从原料合成、工艺放大到制剂成型、临床转化的全链条自主研发生产。

Additionally, our company showcased its core innovative pipeline product——Semaglutide (API) and Semaglutide Injection, deeply positioning in the current high-growth metabolic chronic disease therapeutic area, which became a highlight of this exhibition, attracting multiple customers for in-depth exchanges. Leveraging decades of peptide synthesis technology accumulation and an integrated API plus formulation platform, Hainan Zhonghe Pharmaceutical achieves full-chain autonomous R&D and manufacturing of Semaglutide, spanning from API synthesis, process scale-up, to formulation and clinical transformation.

● 展会深耕交流，深化全球产业协同合作

Deepening Exhibition Engagement, Strengthening Global Industrial Collaboration

展会期间，我司展台人气持续高涨，来自欧洲、东南亚、中东、日韩等多国采购商、药企研发负责人、行业合作伙伴莅临洽谈。公司技术与商务团队一对一精准对接，针对客户多肽原料采购、制剂代工、工艺优化、海外注册、长期供应链合作等需求，提供定制化解决方案，专业的技术实力与完善的产业布局获得海内外客商的高度认可。多肽药物凭借高活性、低毒副作用、靶向性强等优势，已成为全球生物医药创新发展的核心赛道。

During the exhibition, our company's booth maintained consistently high traffic, receiving procurement specialists, R&D directors from pharmaceutical enterprises, and industry partners from Europe, Southeast Asia, the Middle East, Japan, South Korea, and other regions for in-depth negotiations. Our technical and BD teams conducted one-on-one precise matchmaking, providing customized solutions tailored to customer needs spanning peptide API procurement, contract formulation manufacturing, process optimization, overseas registration, and long-term supply chain partnerships—earning high recognition from domestic and international customers for our professional technical capabilities and comprehensive industrial layout. Peptide drugs, leveraging advantages including high activity, low toxicity and side effects, and strong targeting specificity, have become a core track for global biopharmaceutical innovation and development.

本次参展累计达成多项API供货、制剂合作及项目开发意向，进一步拓宽了公司全球化市场布局。

This exhibition cumulatively achieved multiple API supply, formulation collaboration, and project development intentions, further broadening the company's global market footprint.

● 坚守创新初心，持续赋能多肽医药产业发展

Committed to Innovation, Advancing Peptide Pharma Globally

依托多年API+制剂一体化合规运营经验，公司构建了完善的国内外注册申报体系。海南中和药业股份有限公司将持续立足API+制剂一体化核心优势，深耕多肽技术创新与工艺迭代，持续丰富产品管线、扩充合规产能、完善全球服务体系，以高品质、高合规、高性价比的多肽原料药与制剂产品，赋能全球药企创新研发与商业化落地，携手行业伙伴共促生物医药产业高质量发展。

With decades of combined API and formulation expertise under full regulatory compliance, our company has built a robust global regulatory registration system. Moving forward, Hainan Zhonghe Pharmaceutical Co., Ltd. will continue to capitalize on its integrated API + formulation platform, driving peptide innovation and process advancement. We are dedicated to expanding our pipeline, scaling compliant manufacturing capacity, and enhancing worldwide service capabilities—delivering high-quality, regulatory-ready, cost-competitive peptide products that empower partners across the globe to accelerate from discovery to market. Together with industry collaborators, we advance the future of biopharmaceuticals.